Dynavax Technologies Corporation (FRA:DYF1)

Germany flag Germany · Delayed Price · Currency is EUR
9.09
-0.16 (-1.73%)
At close: Dec 5, 2025
-23.68%
Market Cap 1.10B
Revenue (ttm) 281.70M
Net Income (ttm) -36.99M
Shares Out n/a
EPS (ttm) -0.31
PE Ratio n/a
Forward PE 14.74
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 18
Open 9.21
Previous Close 9.25
Day's Range 9.09 - 9.22
52-Week Range 7.65 - 13.57
Beta n/a
RSI 48.61
Earnings Date Feb 19, 2026

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the pr... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1996
Employees 405
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol DYF1
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.